

# Andreas Httmann

## List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8248934/andreas-huttmann-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72

papers

2,680

citations

25

h-index

51

g-index

75

ext. papers

3,564

ext. citations

6.2

avg, IF

4.16

L-index

#	Paper	IF	Citations
72	Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102063	2.2	3
71	Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.. <i>British Journal of Haematology</i> , <b>2022</b>	4.5	1
70	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2101815	2.2	10
69	Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 1	4.9	1
68	FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 3550-3559	8.8	4
67	Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 95	7	0
66	Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. <i>Blood Advances</i> , <b>2021</b> , 5, 2375-2384	7.8	9
65	Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the BUV Method. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 37-42	8.9	12
64	PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>The</b> , <b>2021</b> , 22, 223-234	21.7	29
63	Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. <i>Blood Advances</i> , <b>2021</b> , 5, 2707-2716	7.8	6
62	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , <b>2021</b> ,	44.5	16
61	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2605-2616	2.2	4
60	Metabolic tumor volume, cancer cell fraction, and prognosis - the case of T-cell/histiocyte-rich large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1372-1379	1.9	2
59	Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 872-880	13.4	58
58	Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA). <i>Blood</i> , <b>2020</b> , 136, 39-40	2.2	2
57	The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World. <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	2
56	Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial. <i>Blood</i> , <b>2020</b> , 136, 6-7	2.2	1

55	AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial. <i>Blood</i> , <b>2020</b> , 136, 31-32	2.2	1
54	Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determination. <i>Data in Brief</i> , <b>2020</b> , 28, 104976	1.2	0
53	Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. <i>European Journal of Cancer</i> , <b>2020</b> , 124, 25-36	7.5	35
52	Genetic Variants of the NKG2C/HLA-E Receptor-Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell Lymphoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	1
51	Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy. <i>Cancer Medicine</i> , <b>2020</b> , 9, 8386-8396	4.8	4
50	Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. <i>Hematological Oncology</i> , <b>2020</b> , 38, 244-256	1.3	8
49	Treatment Outcome in Patients with Primary or Secondary Transformed Indolent B-Cell Lymphomas. <i>Oncology Research and Treatment</i> , <b>2019</b> , 42, 580-588	2.8	2
48	Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibition. <i>Vaccine</i> , <b>2019</b> , 37, 6682-6687	4.1	3
47	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 755-757	2.2	1
46	Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG). <i>Leukemia</i> , <b>2019</b> , 33, 439-446	10.7	9
45	Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 67	7	4
44	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , <b>2019</b> , 178, 699-713.e19	56.2	84
43	Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement. <i>European Journal of Haematology</i> , <b>2019</b> , 102, 241-250	3.8	3
42	Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. <i>Annals of Hematology</i> , <b>2019</b> , 98, 897-907	3	15
41	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 393, 229-240	40	283
40	Genomic CDKN2A/2B deletions in adult Ph ALL are adverse despite allogeneic stem cell transplantation. <i>Blood</i> , <b>2018</b> , 131, 1464-1475	2.2	42
39	Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2024-2034	2.2	106
38	Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma: A Phase II Trial (GOAL). <i>Blood</i> , <b>2018</b> , 132, 1678-1678	2.2	1

37	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. <i>Blood</i> , <b>2018</b> , 132, 2861-2861	2.2
36	Interim PET-Based Outcome Prediction in Diffuse Large B-Cell Lymphoma Patients Participating in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) Trial: Comparison of the Delta SUV Max Method and the Deauville 5-Point Scale. <i>Blood</i> , <b>2018</b> , 132, 1186-1191	2.2
35	Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. <i>Blood</i> , <b>2018</b> , 132, 4188-4188	2.2
34	Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 2838-2838	2.2
33	Reply to H.J.A Adams et al and C. Gisselbrecht. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3273-3274	2.2
32	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2845-2853	2.2 164
31	Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. <i>Blood Advances</i> , <b>2018</b> , 2, 2543-2549	7.8 41
30	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. <i>Transplantation</i> , <b>2018</b> , 102, 1914-1923	1.8 8
29	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 536-543	2.2 113
28	Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 1122-1132	12.5 25
27	PET-guided treatment in patients with advanced-stage Hodgkin lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. <i>Lancet, The</i> , <b>2017</b> , 390, 2790-2802	40 173
26	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1691-9	21.7 254
25	Complement Inhibition with Eculizumab in Patients with Cold Agglutinin Disease (CAD): Results from a Prospective Phase II Trial (DECADE Trial). <i>Blood</i> , <b>2015</b> , 126, 274-274	2.2 15
24	Outcomes of Primary and Secondary Transformed B-Cell Lymphomas. <i>Blood</i> , <b>2015</b> , 126, 3894-3894	2.2
23	Immunoglobulin M Heavy/Light Chain Pair Measurement Independently Predicts Clinical Outcome and Refines Prognostic Information Provided By Interim PET in Patients with Aggressive Lymphomas. <i>Blood</i> , <b>2015</b> , 126, 3880-3880	2.2
22	Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. <i>Blood</i> , <b>2014</b> , 124, 3870-9	2.2 188
21	Favorable Outcome in a Large Cohort of Prospectively Treated Adult Patients with T-Lymphoblastic Lymphoma (T-LBL) Despite Slowly Evolving Complete Remission Assessed By Conventional Radiography. <i>Blood</i> , <b>2014</b> , 124, 370-370	2.2 15
20	Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas ■ Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial). <i>Blood</i> , <b>2014</b> , 124, 391-391	2.2 29

19	Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial. <i>Blood</i> , <b>2014</b> , 124, 6-6	2.2	31
18	Programulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia. <i>PLoS ONE</i> , <b>2013</b> , 8, e72107	3.7	22
17	Significant Improvement Of Outcome In Adolescents and Young adults (AYAs) Aged 15-35 Years With Acute Lymphoblastic Leukemia (ALL) With a Pediatric Derived Adult ALL Protocol; Results Of 1529 AYAs In 2 Consecutive Trials Of The German Multicenter Study Group For Adult ALL (GMALL). <i>Blood</i> , <b>2013</b> , 122, 839-839	2.2	34
16	Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. <i>Annals of Hematology</i> , <b>2012</b> , 91, 243-8	3	48
15	Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia. <i>PLoS ONE</i> , <b>2012</b> , 7, e34347	3.7	33
14	Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. <i>Blood</i> , <b>2012</b> , 120, 2032-41	2.2	300
13	High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. <i>Blood</i> , <b>2011</b> , 118, 3504-11	2.2	121
12	Porphyria cutanea tarda. <i>British Journal of Haematology</i> , <b>2010</b> , 148, 493	4.5	
11	Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e488-9; author reply e490-1	2.2	9
10	Prognostic significance of molecular remission in follicular lymphoma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e613; author reply e614	2.2	3
9	Polyclonal Free Light Chain Elevation and Mortality In the German Heinz Nixdorf Recall Study. <i>Blood</i> , <b>2010</b> , 116, 3903-3903	2.2	3
8	Prevalence of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Light-Chain MGUS (LCMGUS) In a Metropolitan Area In Germany. <i>Blood</i> , <b>2010</b> , 116, 4037-4037	2.2	
7	Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. <i>Blood</i> , <b>2009</b> , 113, 3885-6	2.2	78
6	Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 1757-60	1.9	39
5	Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 1053-61	1.9	46
4	Rapid succession of peripheral blood progenitor cell mobilization cycles in patients with chronic heart failure: effects on the hematopoietic system. <i>Transfusion</i> , <b>2006</b> , 46, 1424-31	2.9	3
3	Gene expression profiles in murine hematopoietic stem cells revisited: analysis of cDNA libraries reveals high levels of translational and metabolic activities. <i>Stem Cells</i> , <b>2006</b> , 24, 1719-27	5.8	10
2	Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure--Feasibility, safety and effects on exercise tolerance and cardiac function. <i>Basic Research in Cardiology</i> , <b>2006</b> , 101, 78-86	11.8	45

- 1 Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. *Blood*, **2003**, 101, 2748-55 2.2 68